From: IL-4/10 prevents stress vulnerability following imipramine discontinuation
 | Forward (5′–3′) | Reverse (5′–3′) |
---|---|---|
GAPDH | CATGGCCTTCCGTGTTCCTA | GCGGCACGTCAGATCCA |
BDNF | TGCAGGGGCATAGACAAAAGG | CTTATGAATCGCCAGCCAATTCTC |
IDO | GGCTTCTTCCTCGTCTCTCTATTG | TGACGCTCTACTGCACTGGATAC |
KAT2 | GTTCTCCACACACAAGTCTC | GGATCCATCCTGTCAGTCA |
KMO | CCTGTAGAGGACAATATAGGATCAACAA | GCAAGCCCCATCTACTGCAT |
5-HT1A | CTGTTTATCGCCCTGGATG | ATGAGCCAAGTGAGCGAGAT |
5-HT2A | CCGCTTCAACTCCAGAACCAAAGC | CTTCGAATCATCCTGTACCCGAA |
GATA3 | AGAACCGGCCCCTTATCAA | AGTTCGCGCAGGATGTCC |
TBX21 | AGGGAACCGCTTATATGTCC | TCTCCATCATTCACCTCCAC |
FOXP3 | GAACCCAATGCCCAACCCTAG | TTCTTGGT TTTGAGGTCAAGGG |
RORγ | CCTGGGCTCCTCGCCTGACC | TCTCTCTGCCCTCAGCCTTGCC |
IL-1β | GGCTGGACTGTTTCTAATGC | ATGGTTTCTTGTGACCCTGA |
IL-4 | ACAGGAGAAGGGACGCCATG | GCAGCTTATCGATGAATCCA |
IL-6 | CCACTTCACAAGTCGGAGGCTTA | GCAAGTGCATCATCGTTGTTCATAC |
IL-10 | CCAGTTTTACCTGGTAGAAGTGATG | TGTCTAGGTCCTGGAGTCCAGCAGACTCAA |
IL-13 | TGGGTCCTGTAGATGGCATTG | AGACCAGACTCCCCTGTGCA |
IL-17 | CTCCAGAAGGCCCTCAGACTAC | GGGTCTTCATTGCGGTGG |
IFN-γ | TGA ACG CTA CAC ACT GCA TCT TGG | CGA CTC CTT TTC CGC TTC CTG AG |
TNF-α | GAGTCCGGGCAGGTCTACTTT | CAGGTCACTGTCCCAGCATCT |
CD200R | AAATGCAAATTGCCAAAATTAGA | GTATAGCTAGCATAAGGCTGCATTT |
CD206 | TCTTTGCCTTTCCCAGTCTCC | TGACACCCAGCGGAATTTC |
CX3CR1 | CAGCATCGACCGGTACCTT | GCTGCACTGTCCGGTTGTT |
NOX2 | GACCCAGATGCAGGAAAGGAA | TCATGGTGCACAGCAAAGTGAT |